A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

Clinical trial NCT05990127 · NOT_YET_RECRUITING

Trial details

NCT number: NCT05990127
Sponsor: Akeso
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Locally Advanced or Metastatic NSCLC

Start date: 2023-11-14
Primary completion: 2025-08-05
Enrollment: 642

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.